Streetbeat News

Price Targets

EPAM

Piper Sandler has upgraded EPAM Systems' stock from Neutral to Overweight and raised its price target from $243 to $265. This has resulted in EPAM Systems shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 5:10 pm

BWXT

Alembic Global has downgraded BWX Technologies from Overweight to Neutral and set a price target of $82. The downgrade was announced by analyst Peter Skibitski.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 5:05 pm

ROKU

Roku's stock is trading higher following Susquehanna's decision to maintain a Positive rating and increase its price target from $95 to $100.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 5:03 pm

PYPL

DZ Bank analyst Werner Eisenmann has upgraded PayPal Holdings (NASDAQ:PYPL) from Hold to Buy and announced a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 5:00 pm

DNB

Over the past 3 months, 6 analysts have published their opinion on Dun & Bradstreet Hldgs (NYSE:DNB) stock. The analysts have an average price target of $13.72 versus the current price of Dun & Bradstreet Hldgs at $9.3, implying an upside. This current average has increased by 1.63% from the previous average price target of $13.50.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 5:00 pm

QCOM

DZ Bank analyst Ingo Wermann has upgraded Qualcomm (NASDAQ:QCOM) from Hold to Buy and set a price target of $140.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:58 pm

UBER

Uber Technologies' stock has been upgraded from Sector Weight to Overweight by Keybanc, which also announced a $60 price target for the company's shares.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:58 pm

ITCI

Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and raises the price target from $98 to $101.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:51 pm

CLDX

Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) but lowered the price target from $54 to $52.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:49 pm

UDMY

Cantor Fitzgerald analyst Brett Knoblauch maintains an Overweight rating on Udemy (NASDAQ:UDMY) and raises the price target from $15 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:47 pm